Page 381 - Read Online

Page 16 of 19 Marasco et al. Hepatoma Res 2020;6:33 I http://dx.doi.org/10.20517/2394-5079.2020.01

nationwide survey. Surgery 2008;143:469-75.
106. Xu XF, Xing H, Han J, Li ZL, Lau WY, et al. Risk factors, patterns, and outcomes of late recurrence after liver resection for hepatocellular
carcinoma: a multicenter study from China. In: JAMA Surg 2019;154:209-17.
107. Chan EEH, Chow PKH. A review of prognostic scores after liver resection in hepatocellular carcinoma: the MSKCC, SLICER and
SSCLIP scores. Jpn J Clin Oncol 2016;47:287-93.
108. Testino G, Leone S, Borro P. Alcohol and hepatocellular carcinoma: a review and a point of view. World J Gastroenterol 2014;20:15943-
54.
109. Shinkawa H, Tanaka S, Takemura S, Ito T, Aota T, et al. Obesity and recurrence-free survival in patients with hepatocellular carcinoma
after achieving sustained virological response to interferon therapy for chronic hepatitis C. Ann Gastroenterol Surg 2018;2:319-26.
110. Qin W, Wang L, Hu B, Leng S, Tian H, et al. A novel score predicts HBV-related hepatocellular carcinoma recurrence after hepatectomy:
a retrospective multicenter study. J Gastrointest Surg 2019;23:922-32.
111. Colecchia A, Montrone L, Scaioli E, Bacchi-Reggiani ML, Colli A, et al. Measurement of spleen stiffness to evaluate portal hypertension
and the presence of esophageal varices in patients with HCV-related cirrhosis. Gastroenterology 2012 ;143:646-54.
112. Festi D, Dajti E, Ravaioli F, Marasco G, Colecchia A. Role and clinical meaning of non-invasive tests in the evaluation of portal
hypertension in patients with advanced chronic liver disease. Recenti Prog Med 2018;109:574-84.
113. Marasco G, Colecchia A, Dajti E, Ravaioli F, Cucchetti A, et al. Prediction of posthepatectomy liver failure: role of SSM and LSPS. J
Surg Oncol 2019;119:400-1.
114. Korean Liver Cancer Association (KLCA); National Cancer Center (NCC). 2018 Korean liver cancer association-national cancer center
korea practice guidelines for the management of hepatocellular carcinoma. Korean J Radiol 2019;20:1042-113.
115. Livraghi T, Festi D, Monti F, Salmi A, Vettori C. US-guided percutaneous alcohol injection of small hepatic and abdominal tumors.
Radiology 1986;161:309-12.
116. Shiina S, Tateishi R, Imamura M, Teratani T, Koike Y, et al. Percutaneous ethanol injection for hepatocellular carcinoma: 20-year outcome
and prognostic factors. Liver Int 2012;32:1434-42.
117. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-36.
118. Khan KN, Yatsuhashi H, Yamasaki K, Yamasaki M, Inoue O, et al. Prospective analysis of risk factors for early intrahepatic recurrence of
hepatocellular carcinoma following ethanol injection. J Hepatol 2000;32:269-78.
119. Germani G, Pleguezuelo M, Gurusamy K, Meyer T, Isgrò G, et al. Clinical outcomes of radiofrequency ablation, percutaneous alcohol
and acetic acid injection for hepatocelullar carcinoma: a meta-analysis. J Hepatol 2010;52:380-8.
120. Ebara M, Okabe S, Kita K, Sugiura N, Fukuda H, et al. Percutaneous ethanol injection for small hepatocellular carcinoma: Therapeutic
efficacy based on 20-year observation. J Hepatol 2005;43:458-64.
121. Koda M, Murawaki Y, Mitsuda A, Ohyama K, Horie Y, et al. Predictive factors for intrahepatic recurrence after percutaneous ethanol
injection therapy for small hepatocellular carcinoma. Cancer 2000;88:529-37.
122. Ohnishi K, Yoshioka H, Ito S, Fujiwara K. Prospective randomized controlled trial comparing percutaneous acetic acid injection and
percutaneous ethanol injection for small hepatocellular carcinoma. Hepatology 1998;27:67-72.
123. Shiina S, Tagawa K, Unuma T, Takanashi R, Yoshiura K, et al. Percutaneous ethanol injection therapy for hepatocellular carcinoma. a
histopathologic study. Cancer 1991;68:1524-30.
124. Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Radiofrequency ablation improves prognosis compared with ethanol injection for
hepatocellular carcinoma ≤ 4 cm. Gastroenterology 2004;127:1714-23.
125. Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation,
percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut
2005;54:1151-6.
126. Hines-Peralta A, Liu ZJ, Horkan C, Solazzo S, Goldberg SN. Chemical tumor ablation with use of a novel multiple-tine infusion system
in a canine sarcoma model. J Vasc Interv Radiol 2006;17:351-8.
127. Livraghi T, Meloni F, Di Stasi M, Rolle E, Solbiati L, et al. Sustained complete response and complications rates after radiofrequency
ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice? Hepatology 2008;47:82-9.
128. Lencioni R, Crocetti L. Local-regional treatment of hepatocellular carcinoma. Radiology 2012;262:43-58.
129. Lurje I, Czigany Z, Bednarsch J, Roderburg C, Isfort P, et al. Treatment strategies for hepatocellular carcinoma - a multidisciplinary
approach. Int J Mol Sci 2019;20:1465.
130. Ganne-Carrié N, Nault JC, Ziol M, N’Kontchou G, Nahon P, et al. Predicting recurrence following radiofrequency percutaneous ablation
for hepatocellular carcinoma. Hepatic Oncol 2014;1:395-408.
131. Zytoon AA, Ishii H, Murakami K, El-kholy MR, Furuse J, et al. Recurrence-free survival after radiofrequency ablation of hepatocellular
carcinoma. A registry report of the impact of risk factors on outcome. Jpn J Clin Oncol 2007;37:658-72.
132. Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology 2004;127:S179-88.
133. Sandow TA, Arndt SE, Albar AA, DeVun DA, Kirsch DS, et al. Assessment of response to transcatheter arterial chemoembolization
with doxorubicin-eluting microspheres: tumor biology and hepatocellular carcinoma recurrence in a 5-year transplant cohort. Radiology
2018;286:1072-83.
134. Yamakado K, Takaki H, Nakatsuka A, Yamaknaka T, Fujimori M, et al. Radiofrequency ablation for hepatocellular carcinoma.
Gastrointest Interv 2014;3:35-9.
135. Poon RTP, Lau C, Yu WC, Fan ST, Wong J. High serum levels of vascular endothelial growth factor predict poor response to transarterial
chemoembolization in hepatocellular carcinoma: a prospective study. Oncol Rep 2004;11:1077-84.